|
|
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Ramipril#Pharmacology]] |
| | |
| ==Pharmacokinetics and molecular data==
| |
| <br>
| |
| <font size="4">[[Ramipril pharmacokinetics and molecular data#Absorption|Absorption]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Ramipril pharmacokinetics and molecular data#Distribution|Distribution]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Ramipril pharmacokinetics and molecular data#Metabolism|Metabolism]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Ramipril pharmacokinetics and molecular data#Elimination|Elimination]]</font>
| |
| <br>
| |
| <br>
| |
| | |
| ----------------
| |
| <br>
| |
| <br>
| |
| | |
| ===Absorption===
| |
| | |
| Extent of absorption in GI tract is at least 50% to 60%. T max is 1 h (parent compound) or 2 to 4 h (metabolite, ramiprilat). Bioavailability is 28% (ramipril) or 44% (ramiprilat).
| |
| | |
| ''[[{{PAGENAME}}#Pharmacokinetics and molecular data|Return to top]]''
| |
| <br>
| |
| | |
| ===Distribution===
| |
| | |
| Protein binding is about 73% (parent) or about 56% (metabolite). Plasma concentrations of ramiprilat decline in a triphasic manner: initial rapid decline (representing distribution into peripheral compartment), apparent elimination phase, and terminal elimination phase.
| |
| | |
| ''[[{{PAGENAME}}#Pharmacokinetics and molecular data|Return to top]]''
| |
| <br>
| |
| | |
| ===Metabolism===
| |
| | |
| In liver to active metabolite ramiprilat, which had 6 times the ACE inhibitory activity.
| |
| | |
| ''[[{{PAGENAME}}#Pharmacokinetics and molecular data|Return to top]]''
| |
| <br>
| |
| ===Elimination===
| |
| | |
| Eliminated in urine (60% of parent and metabolites) and feces (40%). Less than 2% of drug recovered in urine is unchanged. The t ½ is less than 50 h (ramiprilat).
| |
| | |
| ''[[{{PAGENAME}}#Pharmacokinetics and molecular data|Return to top]]''
| |
| <br>
| |
| | |
| | |
| {{FDA}}
| |
| | |
| | |
| | |
| | |
| [[Category:Drugs]]
| |